Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Florida College of Medicine, Gainesville, Florida.
BC Children's Hospital Research Institute, University of British Columbia, Vancouver, British Columbia, Canada.
Pediatr Blood Cancer. 2020 Oct;67(10):e28543. doi: 10.1002/pbc.28543. Epub 2020 Aug 11.
Treatment for children with Philadelphia chromosome-positive acute lymphoblastic leukemia has changed radically over the past 20 years. This type of leukemia used to have dismal prognosis, but today cure rates have improved with combination of cytotoxic chemotherapy and a tyrosine kinase inhibitor such as imatinib or dasatinib, with hematopoietic stem cell transplant reserved for patients who are at high risk based on slow response to therapy or who relapse. Treating these patients can be challenging particularly if they are not enrolled on a clinical trial. Here, we describe our approach to these patients.
过去 20 年来，费城染色体阳性急性淋巴细胞白血病患儿的治疗发生了根本性的变化。这种白血病过去预后较差，但如今通过细胞毒性化疗和酪氨酸激酶抑制剂（如伊马替尼或达沙替尼）的联合治疗，以及基于对治疗反应缓慢或复发风险高的患者进行造血干细胞移植，治愈率已经提高。如果这些患者未参加临床试验，治疗这些患者可能具有挑战性。在这里，我们描述了对这些患者的治疗方法。
